BioFortis said this week that the Progressive Multifocal Leukoencephalopathy Consortium, a not-for-profit pharmaceutical collaboration, has selected its Labmatrix and Qiagram software programs to share and manage biospecimen data.
According to BioFortis, researchers in the PML Consortium will use its software to centrally manage de-identified patient clinical profiles and biospecimen information stored in a virtual sample bank; analyze available samples and associated data; request, approve, and track transfers of the samples; and log user interactions and virtual sample bank inventory history.
The PML consortium — which includes Biogen-Idec, Elan, Bristol-Myers Squibb, Pfizer, and Roche — was set up to pool study resources related to progressive multifocal leukoencephalopathy, an often fatal disease in immunocompromised patients that is caused by the John Cunningham virus. The pooled approach is expected to help the researchers derive insights that might not be gained from individual studies.
The group's goal is to reduce the occurrence, morbidity, and mortality of PML using a collaborative approach to data collection, research and analysis, and communication.
Sophie Banzet, who chairs the consortium's board of directors, said in a statement that the BioFortis tools will enable its members to conduct research into PML and its causes in a "collaborative" fashion.